EMICIZUMAB FOR THE TREATMENT OF INFANTS WITH SEVERE HEMOPHILIA A: INTERIM ANALYSIS OF HAVEN 7

被引：0
|
作者：
Pipe, Steven [1 ]
Collins, Peter [1 ]
Dhalluin, Christophe [1 ]
Kenet, Gili [1 ]
Schmitt, Christophe [1 ]
Buri, Muriel [1 ]
Jimenez-Yuste, Victor [1 ]
Peyvandi, Flora [1 ]
Young, Guy [1 ]
Oldenburg, Johannes [1 ]
ElisaMancuso, Maria [1 ]
Kiialainen, Anna [1 ]
Chang, Tiffany [1 ]
Lehle, Michaela [1 ]
Fijnvandraat, Karin [1 ]
机构：
[1] Childrens Hosp Los Angeles, Los Angeles, CA USA
来源：
PEDIATRIC BLOOD & CANCER | 2023年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2011
引用
收藏
页码：S7 / S7
页数：1
相关论文
共 50 条
  • [21] Safety and Outcome of Early Start of Emicizumab in Neonates and Infants with Severe Hemophilia A, a Real-World Experience
    Ahmed, Saad
    Kavanagh, Mary
    Kelly, Imelda
    Ferry, Caitriona
    Mullen, Bertille
    Brady, Bridin
    Nolan, Ruth Hunter
    Nolan, Beatrice
    BLOOD, 2024, 144 : 3976 - 3977
  • [22] Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort
    Barg, Assaf A.
    Avishai, Einat
    Budnik, Ivan
    Levy-Mendelovich, Sarina
    Barazani, Tami B.
    Kenet, Gili
    Livnat, Tami
    PEDIATRIC BLOOD & CANCER, 2019, 66 (11)
  • [23] Successful Treatment with Emicizumab of Patient with Type 2N Normandy and Severe Hemophilia a
    Bryant, Paulette
    Lineberger, Elizabeth
    Carr, Courtney Huckel
    Kaus, Angela
    BLOOD, 2021, 138
  • [24] Transplacental Transfer of Emicizumab: Experience with Emicizumab in a Pregnant Female with Severe Hemophilia. and an Inhibitor
    Kharel, Zeni
    Pruthi, Rajiv K.
    Kouides, Peter A.
    Reid, Robin
    BLOOD, 2023, 142
  • [25] Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: A randomized study (HAVEN 5)
    Yang, Renchi
    Wang, Shujie
    Wang, Xuefeng
    Sun, Jing
    Chuansumrit, Ampaiwan
    Zhou, Jianfeng
    Schmitt, Christophe
    Hsu, Wanling
    Xu, Jeffrey
    Li, Lindong
    Chang, Tiffany
    Zhao, Xielan
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2022, 6 (02)
  • [26] EMICIZUMAB FOR THE MANAGEMENT OF CHILDREN WITH SEVERE HEMOPHILIA A: EXPERIENCE FROM HEMOPHILIA CENTRES IN LITHUANIA
    Trakymiene, Saulyte S.
    Kiudeliene, R.
    Rutkauskiene, G.
    Rascon, J.
    HAEMATOLOGICA, 2021, 106 (09) : 11 - 12
  • [27] Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
    Schmitt, Christophe
    Adamkewicz, Joanne I.
    Xu, Jin
    Petry, Claire
    Catalani, Olivier
    Young, Guy
    Negrier, Claude
    Callaghan, Michael U.
    Levy, Gallia G.
    THROMBOSIS AND HAEMOSTASIS, 2021, 121 (03) : 351 - 360
  • [28] Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3
    Kiialainen, Anna
    Niggli, Markus
    Kempton, Christine L.
    Castaman, Giancarlo
    Chang, Tiffany Y.
    Paz-Priel, Ido
    Adamkewicz, Joanne I.
    Levy, Gallia G.
    BLOOD, 2019, 134
  • [29] COST-CONSEQUENCE ANALYSIS OF EMICIZUMAB PROPHYLAXIS FOR SEVERE HEMOPHILIA A PATIENTS WITHOUT INHIBITORS
    Cortesi, P. A.
    Castaman, G.
    Mantovani, L. G.
    VALUE IN HEALTH, 2020, 23 : S696 - S696
  • [30] Expert opinion paper on the treatment of hemophilia a with emicizumab
    Lopez-Jaime, Francisco-Jose
    Benitez, Olga
    Diaz Jordan, Bolivar Luis
    Montano, Adrian
    Coll, Julia
    Quintana Paris, Laura
    Gomez-del Castillo Solano, Maria Del Carmen
    HEMATOLOGY, 2023, 28 (01)
12345